Eighth Cooley's Anemia Symposium

描述（由申请人提供）：纽约科学院与库利贫血基金会合作，正计划于2005年3月17日至3月19日在佛罗里达州奥兰多举行名为“第八届库利贫血研讨会”的会议。会议由加利福尼亚州奥克兰儿童医院和研究中心血液学/肿瘤学主任Elliott Vichinsky组织。这是该学院和库利贫血基金会就该主题共同组织的第八次国际会议。上一次研讨会是在1997年举行的。在过去的40多年里，这两个组织每隔5到8年就这个问题举行一次会议。这些会议发表的论文集提供了该领域发生的科学进步的丰富历史。第八届库利贫血研讨会的目标是介绍和传播目前的研究结果，并确定地中海贫血基础和临床研究的未来方向。该计划将讨论以下方面的最新进展：1)全球地中海贫血的自然史；2)基因调控与基因治疗；3)地中海贫血铁超载对细胞损伤的机制；4)铁螯合剂的开发与治疗；5)干细胞移植；6)地中海贫血新疗法；7)成人地中海贫血患者；8)非侵入性铁测量。该研讨会将整合基础科学和临床研究，以便实验室研究人员和临床医生能够相互了解地中海贫血的最新进展。与会者应了解地中海贫血疾病的分子生物学、病理生理学、流行病学、临床护理和社会心理管理。主题演讲、讲座、研讨会、小组讨论和海报展示的组合将全面概述地中海贫血的理解和治疗进展。我们期待此次会议将吸引来自分子生物学、细胞生物学、血液学、骨髓与干细胞移植、流行病学、铁生物化学与螯合、输血医学等领域的资深研究人员、博士后和行业科学家的广泛参与。

DESCRIPTION (provided by applicant): The New York Academy of Sciences, in partnership with the Cooley's Anemia Foundation, is planning a conference titled, Eighth Cooley's Anemia Symposium, to be held from March 17 to March 19, 2005 in Orlando, FL. It is being organized by Elliott Vichinsky, Director, Hematology/Oncology at the Children's Hospital and Research Center in Oakland, CA. This is the eighth international conference that the Academy and the Cooley's Anemia Foundation are co-organizing on the subject. The last symposium was held in 1997. The two organizations have held a conference on the subject every 5 to 8 years dating over the past forty or so years. The published proceedings from these meetings provide a rich history of the scientific advancements that have occurred in the field. The goal of the Eighth Cooley's Anemia Symposium is the presentation and dissemination of current findings and the setting of future directions regarding basic and clinical research in thalassemia. The program will address recent advances in: 1) natural history of thalassemia world-wide; 2) gene regulation and gene therapy; 3) mechanisms of cell injury of iron overload in thalassemia; 4) development and therapy of iron chelators; 5) stem cell transplantation; 6) new therapies for thalassemia; 7) the adult thalassemia patient; and 8) non-invasive iron measurements. The symposium will integrate basic science and clinical research so that both bench researchers and clinicians can develop a mutual understanding of recent progress in thalassemia. Conference attendees should achieve an understanding of the molecular biology, pathophysiology, epidemiology, clinical care and psychosocial management of thalassemic disorders. A combination of keynote addresses, lectures, workshops, panel discussions, and poster presentations will provide a comprehensive overview of progress in the understanding and treatment of thalassemia. We anticipate that the conference will attract wide participation among senior investigators, postdoctorate fellows, and industry scientists working in the fields of molecular biology, cell biology, hematology, bone marrow & stem cell transplantation, epidemiology, iron biochemistry & chelation, and transfusion medicine.